AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 OCT 10 - (NewsRx.com & NewsRx.net) -- Quintiles Transnational Corp. (QTRN) and Columbia Laboratories, Inc., (COB) announced an agreement to commercialize Columbia's portfolio of women's healthcare products in the United States.
Under the terms of this agreement, Quintiles' commercialization unit, Innovex, will provide a dedicated team of 55 sales representatives on a 3-year, fee-for-service basis, to commercialize the following products:
{bullet} Prochieve 8%, approved for progesterone supplementation or replacement as part of an assisted reproductive technology (ART) treatment for infertile women with progesterone deficiency and secondary amenorrhea;
{bullet} Prochieve 4%, approved for secondary amenorrhea;
{bullet} Advantage-S, a spermicidal contraceptive;
{bullet} RepHresh Vaginal Gel, a feminine hygiene product.
In addition to ...